These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24974683)

  • 1. Haptoglobin 2-2 phenotype is associated with decreased serum iron levels in endstage renal disease patients resistant to rhEPO therapy.
    Martins F; Catarino C; Rocha-Pereira P; Reis F; Sameiro-Faria M; Miranda V; Belo L; Bronze-da-Rocha E; Costa E; Santos-Silva A
    Br J Biomed Sci; 2014; 71(2):79-81. PubMed ID: 24974683
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin.
    Kooistra MP; van Es A; Struyvenberg A; Marx JJ
    Br J Haematol; 1991 Dec; 79(4):634-9. PubMed ID: 1772785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
    Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis: analysis of 702 patients after 10-year follow-up.
    Chang HC; Chen CL; Chiu TL; Chen SI; Yen AM; Chen TH
    Public Health Nutr; 2009 Dec; 12(12):2410-5. PubMed ID: 19344540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiological aspects of red blood cells in end-stage renal disease patients resistant to recombinant human erythropoietin therapy.
    Georgatzakou HT; Tzounakas VL; Kriebardis AG; Velentzas AD; Papageorgiou EG; Voulgaridou AI; Kokkalis AC; Antonelou MH; Papassideri IS
    Eur J Haematol; 2017 Jun; 98(6):590-600. PubMed ID: 28295628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency.
    Bedani PL; Cecchetti E; Gilli P
    Nephron; 1995; 71(4):459-60. PubMed ID: 8587628
    [No Abstract]   [Full Text] [Related]  

  • 8. Current perspectives: iron management during therapy with recombinant human erythropoietin.
    York S
    ANNA J; 1993 Dec; 20(6):645-50; quiz 651-2. PubMed ID: 8267408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron management during treatment with recombinant human erythropoietin in chronic renal failure.
    Watson A
    J Clin Pharmacol; 1993 Dec; 33(12):1134-8. PubMed ID: 8126248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
    Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
    Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
    Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
    Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo effects of recombinant human erythropoietin on circulating human hemopoietic progenitor cells.
    Ganser A; Bergmann M; Völkers B; Grützmacher P; Scigalla P; Hoelzer D
    Exp Hematol; 1989 Jun; 17(5):433-5. PubMed ID: 2714423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk.
    Costa-Mallen P; Zabetian CP; Agarwal P; Hu SC; Yearout D; Samii A; Leverenz JB; Roberts JW; Checkoway H
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1087-92. PubMed ID: 26228081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of magnesium and zinc levels in blood in end stage renal disease patients treated by hemodialysis or peritoneal dialysis.
    Pietrzak I; Bladek K; Bulikowski W
    Magnes Res; 2002 Dec; 15(3-4):229-36. PubMed ID: 12635877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients.
    do Sameiro-Faria M; Ribeiro S; Rocha-Pereira P; Fernandes J; Reis F; Bronze-da-Rocha E; Miranda V; Quintanilha A; Costa E; Belo L; Santos-Silva A
    Ren Fail; 2013; 35(10):1392-8. PubMed ID: 23991655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved response to erythropoietin therapy with long-term continuous iron supplementation.
    Descombes E; Fellay G
    Nephron; 2000 Feb; 84(2):196-7. PubMed ID: 10657727
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of recombinant erythropoietin on electrolytes and nutrition in end-stage renal disease patients.
    Kaupke CJ; Vaziri ND
    Int J Artif Organs; 1993 Feb; 16(2):59-62. PubMed ID: 8486413
    [No Abstract]   [Full Text] [Related]  

  • 20. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy.
    Schaefer RM; Schaefer L
    J Perinat Med; 1995; 23(1-2):83-8. PubMed ID: 7658326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.